SCHEMBL18401481

SCHEMBL18401481

CCc1ccc(C(O)C(C)N)cc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.66
TDP1 Q9NUW8 6/20 0.66
LMNA P02545 6/20 0.66
RECQL P46063 4/20 0.66
MAPT P10636 4/20 0.66
HIF1A Q16665 4/20 0.66
BLM P54132 3/20 0.66
ALOX15 P16050 2/20 0.66
TSHR P16473 1/20 0.66
NFKB1 P19838 1/20 0.66
THPO P40225 1/20 0.66
HSD17B10 Q99714 1/20 0.66
POLB P06746 1/20 0.66
APEX1 P27695 1/20 0.66
MTOR P42345 1/20 0.66
KMT2A Q03164 1/20 0.66
ADRA1A P35348 2/20 0.50
MAPK1 P28482 1/20 0.50
ADRB1 P08588 1/20 0.50
MIF P14174 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16216247 0.87 KDM4E (0.47) KDM4ETDP1LMNARECQLMAPT
SCHEMBL21557010 0.86 KDM4E (0.66) KDM4ETDP1LMNARECQLMAPT
SCHEMBL21556948 0.85 KDM4E (0.64) KDM4ETDP1LMNARECQLMAPT
SCHEMBL10305413 0.85 KDM4E (0.64) KDM4ETDP1LMNARECQLMAPT
SCHEMBL20852494 0.81 KDM4E (0.58) KDM4ETDP1LMNARECQLMAPT
SCHEMBL922053 0.80 ALOX15 (0.44) KDM4ETDP1LMNARECQLMAPT
SCHEMBL4109681 0.80 TRPA1 (0.55) KDM4ETDP1MAPTHIF1AALOX15
Levonordefrin SCHEMBL6295856 0.80 TDP1 (1.00) KDM4ETDP1LMNARECQLMAPT
Levonordefrin SCHEMBL14478222 0.80 TDP1 (1.00) KDM4ETDP1LMNARECQLMAPT
Nordefrin SCHEMBL249722 0.80 TDP1 (1.00) KDM4ETDP1LMNARECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200397927-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-12-24 US disclosed
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-09-21 US disclosed
US-9550000-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2017-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 KDM4E 3637/4885TDP1 1114/4885LMNA 1311/4885
US-20200397927-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 KDM4E 3637/4885TDP1 1114/4885LMNA 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.